Elixir confident in targeting new sub-basin


Published 16-JAN-2020 15:11 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Elixir Energy Limited (ASX:EXR) has provided an update in relation to its upcoming drilling operations in its 100% owned Nomgon IX Coal Bed Methane Production Sharing Contract in Mongolia, in particular highlighting the prospects of Nomgon-1, a new well that has just spudded.

This is the company’s second well in its two core-hole drilling program.

Nomgon-1 lies approximately 37 kilometres to the south-west of the recently drilled Ugtaal-1 well and is situated in a different Permian sub-basin to the latter.

Encouragingly, this is one of many such sub-basins in the very large Nomgon IX PSC, underlining the importance of Elixir’s 30,000 square kilometre land holding that covers a major Permian coal bearing basin and the options that it offers as the group’s exploration strategy unfolds.

Management has a good understanding of the location where Nomgon-1 is situated as it was first identified as being prospective for coal seam gas (CSG) exploration by Elixir’s subsidiary company four years ago when it undertook initial on-ground prospecting work across the PSC area.

Recent field work has re-affirmed the location’s strong potential, with the confirmation of thick outcropping coal seams that demonstrate good cleating and coal quality to the naked eye.

Assessment of Ugtaal-1 assists in targeting Nomgon-1

Transitioning to Nomgon-1 is timely as management noted today that the results from Ugtaal-1, which was its key focus recently, were at the lower end of expectations due to factors such as poorer than anticipated coal quality.

While preliminary findings also reflected this lower than expected coal quality, the process of continuing with ongoing desorption work and supplementary laboratory testing is providing valuable information for the company’s ongoing exploration efforts over the multiple targeted Permian sub-basins within the overall PSC area.

Release of 2020 exploration strategy imminent

Management’s plans for 2020 have recently been proposed to Mongolia’s petroleum regulator, as required under the terms of its PSC.

These include a mixture of further low cost seismic and drilling.

By their nature, these will be dynamic over the course of the year as the two processes feed off each other and the final results of the current program.

A mandatory formal annual meeting with the regulator is scheduled to be held towards the end of January.

The 2019 results and 2020 plans will be discussed at that meeting.

Expressing his confidence regarding the Nomgon-1 drilling program, Elixir’s managing director Neil Young said, “We are looking forward to the last of the core-hole wells planned for our first year’s drilling campaign.

‘’The Nomgon-1 well is one which we are highly confident will intersect coal seams at depth, providing a good first test of a different sub-basin in the PSC.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free